Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 150

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 150
---
| Indirect and unallocated expenses        |     |                         |        |     |   |       |     |   |        |
| Personnel-related                        |     |                         |  3,689 |     |   | 1,552 |     |   |  2,137 |
| Consulting and other                     |     |                         |    998 |     |   |   165 |     |   |    833 |
| Total research and development expenses  |     | $                       | 51,171 |     | $ | 7,845 |     | $ | 43,326 |

Research and development expenses were $51.2 million for the year ended December 31, 2024, compared to $7.8 million for the year ended December 31, 2023 . The increase of $43.4 million was primarily due to: (i) a $37.0 million increase in clinical trial expenses related to the conduct of our Phase 2 trial of LB-102in the treatment of patients with acute schizophrenia, the majority of which took place in 2024; (ii) a $2.1 million 100

increase in personnel-related expenses related to an increase in headcount; (iii) a $1.8 million increase in formulation and CMC expenses due to the
scale-up and production of LB-102 to be used for clinical and preclinical development; and (iv) a $1.6 million increase in preclinical research expenses
related to the continued clinical development of LB-102 for schizophrenia and other indications.

General and Administrative Expenses

General and administrative expenses were $13.7 million for the year ended December 31, 2024,
compared to $3.5 million for the year ended December 31, 2023 . The increase of $10.1 million was primarily due to: (i) a $3.2 million increase related to the write off of deferred offering costs; (ii) a
$2.3 million increase in stock-based compensation primarily related to modifications of outstanding stock options of our former chief executive officer; (iii) a $1.3 million increase in personnel-related costs related to increased
headcount (including the hiring of a chief executive officer and chief financial officer) and merit increases; (iv) a $0.8 million increase in termination benefits related to the resignation of our former chief executive officer;
(v) a $0.7 million increase in consulting expenses primarily related to